Literature DB >> 25794587

[Value of perineal HistoScanning™ template-guided prostate biopsy].

M F Hamann1, C Hamann2, D Olzem2, A Trettel2, K P Juenemann2, C M Naumann2.   

Abstract

BACKGROUND: Modern imaging modalities improve prostate diagnostics.
OBJECTIVES: This study was performed to determine the outcome characteristics of biopsy procedures using the results of HistoScanning(TM) analysis (HS) for identifying prostate cancer (PCa) in patients with perineal template-guided prostate biopsy. PATIENTS AND METHODS: A total of 104 consecutive men (mean age 69 years, mean PSA 9.9 ng/ml) underwent HS prior to the extended prostate biopsy procedure. Patients received a targeted transperineal (template-assisted) as well as a targeted transrectal prostate biopsy using HS projection reports supplemented by a standardized 14-core systematic transrectal prostate biopsy (Bx). The cancer detection rate was analyzed on the sector level and HS targeted results were correlated to biopsy outcome, sensitivity, specificity, predictive accuracy, negative predictive value (NPV) and positive predictive value (PPV).
RESULTS: Of 104 patients, 44 patients (42%) were found to have PCa. Histology detected atypical small acinar proliferation in 3 patients (2.9%), high-grade prostatic intraepithelial neoplasia in 16 (15.4%), and chronic active inflammation in 74 (71.1%), respectively. The detection rate for each region was significantly higher in HS-targeted biopsies compared to Bx. The detection rate per patient was not significantly different, although a smaller number of regions were biopsied with the targeted approach. The overall sensitivity, specificity, predictive accuracy, NPV, and PPV on the sector level were 37.2, 85.6, 78.6, 88.7 and 30.8%, respectively.
CONCLUSION: The use of HS analysis results in a higher detection rate of prostate cancer compared to common transrectal ultrasonography (TRUS)-guided Bx. This technique increases the informative value of TRUS imaging and improves the diagnostic impact at least in the targeted biopsy setting.

Entities:  

Keywords:  Early detection of cancer; High-intensity focused, transrectal; Prostate cancer; Prostatic intraepithelial neoplasia; Prostatitis

Mesh:

Year:  2015        PMID: 25794587     DOI: 10.1007/s00120-014-3731-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

Review 1.  The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis.

Authors:  Peng-Fei Shen; Yu-Chun Zhu; Wu-Ran Wei; Yong-Zhong Li; Jie Yang; Yu-Tao Li; Ding-Ming Li; Jia Wang; Hao Zeng
Journal:  Asian J Androl       Date:  2011-11-21       Impact factor: 3.285

2.  Prostate cancer incidence and mortality trends in 37 European countries: an overview.

Authors:  F Bray; J Lortet-Tieulent; J Ferlay; D Forman; A Auvinen
Journal:  Eur J Cancer       Date:  2010-11       Impact factor: 9.162

3.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

Review 4.  Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature.

Authors:  Felix K-H Chun; Jonathan I Epstein; Vincenzo Ficarra; Stephen J Freedland; Rodolfo Montironi; Francesco Montorsi; Shahrokh F Shariat; Fritz H Schröder; Vincenzo Scattoni
Journal:  Eur Urol       Date:  2010-09-04       Impact factor: 20.096

5.  Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™).

Authors:  Lucy A M Simmons; Philippe Autier; Frantiŝek Zát'ura; Johan Braeckman; Alexandre Peltier; Imre Romic; Arnulf Stenzl; Karien Treurnicht; Tara Walker; Dror Nir; Caroline M Moore; Mark Emberton
Journal:  BJU Int       Date:  2011-11-17       Impact factor: 5.588

6.  Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate.

Authors:  J Schiffmann; P Tennstedt; J Fischer; Zhe Tian; B Beyer; K Boehm; M Sun; G Gandaglia; U Michl; M Graefen; G Salomon
Journal:  World J Urol       Date:  2014-05-29       Impact factor: 4.226

7.  Utility of Histoscanning™ prior to prostate biopsy for the diagnosis of prostate adenocarcinoma.

Authors:  C Núñez-Mora; J M García-Mediero; P Patiño; C Orellana; A Garrido; A Rojo; D Rendón
Journal:  Actas Urol Esp       Date:  2013-03-16       Impact factor: 0.994

8.  Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy.

Authors:  Georg Salomon; Jens Köllerman; Imke Thederan; Felix K H Chun; Lars Budäus; Thorsten Schlomm; Hendrik Isbarn; Hans Heinzer; Hartwig Huland; Markus Graefen
Journal:  Eur Urol       Date:  2008-03-10       Impact factor: 20.096

9.  Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies.

Authors:  Saqib Javed; Eliot Chadwick; Albert A Edwards; Sabeena Beveridge; Robert Laing; Simon Bott; Christopher Eden; Stephen Langley
Journal:  BJU Int       Date:  2014-03-20       Impact factor: 5.588

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.